Follicular Lymphoma (FL) Third-Line and Beyond Therapy: T-cell engager bispecific antibodies: Added epcoritamab-bysp as a Category 2A preferred recommendation. CAR-T cell therapy: Added lisocabtagene maraleucel (CD19-targeted) as a Category 2A…
NCCN Clinical Practice Guidelines: B-Cell Lymphomas (2024.V2)
